Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.

You may also be interested in...



Pfizer And Taisho Reach Deal for Schizophrenia Candidate

Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.

Pfizer And Taisho Reach Deal for Schizophrenia Candidate

Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.

Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor

Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel